2026 Q1 -tulosraportti
90 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,82%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5 t sittenExcerpt from Reuters article today Analysts point out that the big question is whether Novo is now at a turning point where growth can begin again. Expectations for 2026 have improved, partly because generic competition against Wegovy is expected later than previously feared. Novo is also trying to change market perception through a more aggressive strategy. However, the lawsuit against Lilly is not necessarily expected to significantly change competition, but could be an attempt to create awareness and influence investors' view of the company. Overall, the assessment is that Novo Nordisk still faces a tough battle against Eli Lilly, but that the company has gained more momentum. For investors, the most important positive sign may be that the period of constant crises and profit warnings appears to be coming to an end.
According to analysts, it's always only Novo that "faces a tough battle"... never Eli (?) Admittedly, Eli is raking in tons of money from Zepbound and Mounjaro.. for now.. but it's no longer the case that everyone needs a huge truck when there are now easy-to-drive sports cars in pill form on the market . Novo's little sports car comes with both seatbelts, airbags and a reasonably powerful engine. Foundayo GTI unfortunately does not come with this but you mostly get from A to B anyway, unless you get carsick then. If you are one of those who still need a truck, Novo offers free trade-in on the same day as they have approximately similar driving characteristics.. and free exchange back if a truck wasn't for you... if you drive Foundayo, however, you have to get a truck license if you want to switch.. quite a big difference there then.. Ahh.. almost forgot.. are you a woman? like the risk that comes with Foundayo? go for it! ..but remember condoms on the trip 😉
·6 t sitten · MuokattuGet out the long-term glasses, boys. Away with the daytrader crybabies. Do like the girls. Buy NN and forget you bought it. Set the egg timer 3 years ahead and then take a look. Good evening 🙏
·6 t sittenBiggest hypesters on this site don't know much about Novo's pipeline.NOVO NORDISK PIPELINE – NOW AND THE NEXT YEARS (2026-2030) Novo Nordisk's future depends especially on whether the company can build on the success of Ozempic and Wegovy. The most important areas are obesity, diabetes, MASH (fatty liver) and rare diseases. 1. OBESITY – THE MOST IMPORTANT GROWTH DRIVER CagriSema (cagrilintide + semaglutide) - Combination of amylin analog and GLP-1. - One of Novo's most important next-generation obesity treatments. - To replace or supplement Wegovy. - Potential to become a blockbuster product. Amycretin / Zenagamtide - New molecule combining GLP-1 and amylin effects. - One of the most exciting long-term candidates. - The goal is greater weight loss and better effect than semaglutide. - Can become an important growth driver after 2028. Oral Wegovy (semaglutide tablet) - Tablet version of Wegovy. - Can make treatment easier and expand the market. - Large commercial opportunity because many patients prefer tablets over injections. Semaglutide higher dose (7.2 mg) - Higher dose Wegovy. - To increase weight loss and extend the lifespan of the semaglutide platform. 2. DIABETES – NEXT GENERATION IcoSema - Combination of insulin icodec and semaglutide. - The goal is fewer injections and simpler diabetes treatment. Awiqli (insulin icodec) - Weekly basal insulin. - Can change the market for insulin treatment. Other research areas: - New oral diabetes treatments. - New GLP-1-based treatments. - More advanced insulin forms. 3. MASH (FATTY LIVER) Efruxifermin (EFX) - FGF21-based treatment. - Developed for MASH (metabolic fatty liver disease). - A potentially large market because obesity and fatty liver are often linked. 4. RARE DISEASES Novo is working with, among others: Etavopivat - Treatment for blood diseases such as thalassemia. Zaltenibart - Treatment for PNH (rare blood disease). NDec - Research area within sickle cell disease. 5. LONG-TERM RESEARCH Novo is working on the next generation of obesity treatments: - GLP-1 + GIP combinations. - GLP-1 + glucagon. - Triple-agonists. - New hormone-based treatments. The Goal: - More weight loss. - Fewer side effects. - Better metabolic control. EXPECTED TIMELINE 2026: - Important data from CagriSema and new obesity projects. - Focus on oral Wegovy and higher doses. 2027-2028: - Possible new approvals. - Expansion of the obesity portfolio. 2028-2030: - Amycretin and next-generation molecules can become the major growth drivers. BIGGEST OPPORTUNITIES 1. Amycretin - Biggest long-term potential. - Can become Novo's next big obesity medicine. 2. CagriSema - Most likely short-term growth driver. 3. Oral Wegovy - Large commercial impact. 4. MASH - Can open a completely new billion-dollar market.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
90 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,82%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenExcerpt from Reuters article today Analysts point out that the big question is whether Novo is now at a turning point where growth can begin again. Expectations for 2026 have improved, partly because generic competition against Wegovy is expected later than previously feared. Novo is also trying to change market perception through a more aggressive strategy. However, the lawsuit against Lilly is not necessarily expected to significantly change competition, but could be an attempt to create awareness and influence investors' view of the company. Overall, the assessment is that Novo Nordisk still faces a tough battle against Eli Lilly, but that the company has gained more momentum. For investors, the most important positive sign may be that the period of constant crises and profit warnings appears to be coming to an end.According to analysts, it's always only Novo that "faces a tough battle"... never Eli (?) Admittedly, Eli is raking in tons of money from Zepbound and Mounjaro.. for now.. but it's no longer the case that everyone needs a huge truck when there are now easy-to-drive sports cars in pill form on the market . Novo's little sports car comes with both seatbelts, airbags and a reasonably powerful engine. Foundayo GTI unfortunately does not come with this but you mostly get from A to B anyway, unless you get carsick then. If you are one of those who still need a truck, Novo offers free trade-in on the same day as they have approximately similar driving characteristics.. and free exchange back if a truck wasn't for you... if you drive Foundayo, however, you have to get a truck license if you want to switch.. quite a big difference there then.. Ahh.. almost forgot.. are you a woman? like the risk that comes with Foundayo? go for it! ..but remember condoms on the trip 😉
- ·6 t sitten · MuokattuGet out the long-term glasses, boys. Away with the daytrader crybabies. Do like the girls. Buy NN and forget you bought it. Set the egg timer 3 years ahead and then take a look. Good evening 🙏
- ·6 t sittenBiggest hypesters on this site don't know much about Novo's pipeline.NOVO NORDISK PIPELINE – NOW AND THE NEXT YEARS (2026-2030) Novo Nordisk's future depends especially on whether the company can build on the success of Ozempic and Wegovy. The most important areas are obesity, diabetes, MASH (fatty liver) and rare diseases. 1. OBESITY – THE MOST IMPORTANT GROWTH DRIVER CagriSema (cagrilintide + semaglutide) - Combination of amylin analog and GLP-1. - One of Novo's most important next-generation obesity treatments. - To replace or supplement Wegovy. - Potential to become a blockbuster product. Amycretin / Zenagamtide - New molecule combining GLP-1 and amylin effects. - One of the most exciting long-term candidates. - The goal is greater weight loss and better effect than semaglutide. - Can become an important growth driver after 2028. Oral Wegovy (semaglutide tablet) - Tablet version of Wegovy. - Can make treatment easier and expand the market. - Large commercial opportunity because many patients prefer tablets over injections. Semaglutide higher dose (7.2 mg) - Higher dose Wegovy. - To increase weight loss and extend the lifespan of the semaglutide platform. 2. DIABETES – NEXT GENERATION IcoSema - Combination of insulin icodec and semaglutide. - The goal is fewer injections and simpler diabetes treatment. Awiqli (insulin icodec) - Weekly basal insulin. - Can change the market for insulin treatment. Other research areas: - New oral diabetes treatments. - New GLP-1-based treatments. - More advanced insulin forms. 3. MASH (FATTY LIVER) Efruxifermin (EFX) - FGF21-based treatment. - Developed for MASH (metabolic fatty liver disease). - A potentially large market because obesity and fatty liver are often linked. 4. RARE DISEASES Novo is working with, among others: Etavopivat - Treatment for blood diseases such as thalassemia. Zaltenibart - Treatment for PNH (rare blood disease). NDec - Research area within sickle cell disease. 5. LONG-TERM RESEARCH Novo is working on the next generation of obesity treatments: - GLP-1 + GIP combinations. - GLP-1 + glucagon. - Triple-agonists. - New hormone-based treatments. The Goal: - More weight loss. - Fewer side effects. - Better metabolic control. EXPECTED TIMELINE 2026: - Important data from CagriSema and new obesity projects. - Focus on oral Wegovy and higher doses. 2027-2028: - Possible new approvals. - Expansion of the obesity portfolio. 2028-2030: - Amycretin and next-generation molecules can become the major growth drivers. BIGGEST OPPORTUNITIES 1. Amycretin - Biggest long-term potential. - Can become Novo's next big obesity medicine. 2. CagriSema - Most likely short-term growth driver. 3. Oral Wegovy - Large commercial impact. 4. MASH - Can open a completely new billion-dollar market.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
90 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
3,82%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenExcerpt from Reuters article today Analysts point out that the big question is whether Novo is now at a turning point where growth can begin again. Expectations for 2026 have improved, partly because generic competition against Wegovy is expected later than previously feared. Novo is also trying to change market perception through a more aggressive strategy. However, the lawsuit against Lilly is not necessarily expected to significantly change competition, but could be an attempt to create awareness and influence investors' view of the company. Overall, the assessment is that Novo Nordisk still faces a tough battle against Eli Lilly, but that the company has gained more momentum. For investors, the most important positive sign may be that the period of constant crises and profit warnings appears to be coming to an end.According to analysts, it's always only Novo that "faces a tough battle"... never Eli (?) Admittedly, Eli is raking in tons of money from Zepbound and Mounjaro.. for now.. but it's no longer the case that everyone needs a huge truck when there are now easy-to-drive sports cars in pill form on the market . Novo's little sports car comes with both seatbelts, airbags and a reasonably powerful engine. Foundayo GTI unfortunately does not come with this but you mostly get from A to B anyway, unless you get carsick then. If you are one of those who still need a truck, Novo offers free trade-in on the same day as they have approximately similar driving characteristics.. and free exchange back if a truck wasn't for you... if you drive Foundayo, however, you have to get a truck license if you want to switch.. quite a big difference there then.. Ahh.. almost forgot.. are you a woman? like the risk that comes with Foundayo? go for it! ..but remember condoms on the trip 😉
- ·6 t sitten · MuokattuGet out the long-term glasses, boys. Away with the daytrader crybabies. Do like the girls. Buy NN and forget you bought it. Set the egg timer 3 years ahead and then take a look. Good evening 🙏
- ·6 t sittenBiggest hypesters on this site don't know much about Novo's pipeline.NOVO NORDISK PIPELINE – NOW AND THE NEXT YEARS (2026-2030) Novo Nordisk's future depends especially on whether the company can build on the success of Ozempic and Wegovy. The most important areas are obesity, diabetes, MASH (fatty liver) and rare diseases. 1. OBESITY – THE MOST IMPORTANT GROWTH DRIVER CagriSema (cagrilintide + semaglutide) - Combination of amylin analog and GLP-1. - One of Novo's most important next-generation obesity treatments. - To replace or supplement Wegovy. - Potential to become a blockbuster product. Amycretin / Zenagamtide - New molecule combining GLP-1 and amylin effects. - One of the most exciting long-term candidates. - The goal is greater weight loss and better effect than semaglutide. - Can become an important growth driver after 2028. Oral Wegovy (semaglutide tablet) - Tablet version of Wegovy. - Can make treatment easier and expand the market. - Large commercial opportunity because many patients prefer tablets over injections. Semaglutide higher dose (7.2 mg) - Higher dose Wegovy. - To increase weight loss and extend the lifespan of the semaglutide platform. 2. DIABETES – NEXT GENERATION IcoSema - Combination of insulin icodec and semaglutide. - The goal is fewer injections and simpler diabetes treatment. Awiqli (insulin icodec) - Weekly basal insulin. - Can change the market for insulin treatment. Other research areas: - New oral diabetes treatments. - New GLP-1-based treatments. - More advanced insulin forms. 3. MASH (FATTY LIVER) Efruxifermin (EFX) - FGF21-based treatment. - Developed for MASH (metabolic fatty liver disease). - A potentially large market because obesity and fatty liver are often linked. 4. RARE DISEASES Novo is working with, among others: Etavopivat - Treatment for blood diseases such as thalassemia. Zaltenibart - Treatment for PNH (rare blood disease). NDec - Research area within sickle cell disease. 5. LONG-TERM RESEARCH Novo is working on the next generation of obesity treatments: - GLP-1 + GIP combinations. - GLP-1 + glucagon. - Triple-agonists. - New hormone-based treatments. The Goal: - More weight loss. - Fewer side effects. - Better metabolic control. EXPECTED TIMELINE 2026: - Important data from CagriSema and new obesity projects. - Focus on oral Wegovy and higher doses. 2027-2028: - Possible new approvals. - Expansion of the obesity portfolio. 2028-2030: - Amycretin and next-generation molecules can become the major growth drivers. BIGGEST OPPORTUNITIES 1. Amycretin - Biggest long-term potential. - Can become Novo's next big obesity medicine. 2. CagriSema - Most likely short-term growth driver. 3. Oral Wegovy - Large commercial impact. 4. MASH - Can open a completely new billion-dollar market.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt